Burkholderia Gladioli – A Predictor of Poor Outcome in Cystic Fibrosis Patients Who Receive Lung Transplants? A Case of Locally Invasive Rhinosinusitis and Persistent Bacteremia in...

Article in Canadian respiratory journal: journal of the Canadian Thoracic Society · July 2011
Impact Factor: 1.66 · DOI: 10.1155/2011/304179 · Source: PubMed

CITATIONS 3
READS 174

7 authors, including:

Bradley S Quon
University of British Columbia - Vancouver
45 PUBLICATIONS 422 CITATIONS

Amin R Javer
University of British Columbia - Vancouver
81 PUBLICATIONS 814 CITATIONS

All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately.

Available from: Amin R Javer
Retrieved on: 16 June 2016
**CASE REPORT**

*Burkholderia gladioli – a predictor of poor outcome in cystic fibrosis patients who receive lung transplants? A case of locally invasive rhinosinusitis and persistent bacteremia in a 36-year-old lung transplant recipient with cystic fibrosis*  

Bradley S Quon MD FRCPC1, James D Reid MD2, Patrick Wong BSc3, Pearce G Wilcox MD FRCPC1, Amin Javer MD FRSCC2, Jennifer M Wilson MD FRCPC1,3, Robert D Levy MD FRCP FCCP1,3

There have been very few reports describing postlung transplant outcomes in patients infected/colonized with *Burkholderia gladioli* pretransplant. A case involving a lung transplant recipient with cystic fibrosis who ultimately died as a result of severe rhinosinusitis due to *B gladioli* infection in the context of postlung transplant immunosuppression is reported.

**Key Words:** Bacteremia; Case report; Cystic fibrosis; Lung transplant; Opportunistic infection

*Burkholderia gladioli* are ubiquitous Gram-negative bacteria that are able to occupy diverse environments including soil, plants and the respiratory tract of humans (1). Although *B gladioli* have traditionally been recognized as plant pathogens, they are increasingly being reported to cause infections in humans. They are closely related to *Burkholderia cepacia* complex, which are well known for their ability to cause severe illness in cystic fibrosis patients. Based on poor postlung transplant outcomes, prelung transplant infection/colonization with *B cepacia* complex is currently an absolute contraindication for lung transplantation in many lung transplant centres in North America (2).

**CASE PRESENTATION**

A 36-year-old woman with advanced cystic fibrosis (CF) lung disease underwent bilateral lung transplantation in 2007. Her pretransplant history was notable for repeated pulmonary exacerbations involving methicillin-resistant *Staphylococcus aureus* (MRSA) and *Burkholderia gladioli*, but without clinically significant sinus disease requiring investigations and/or treatment. Ten months post-transplant, she presented with a right frontal headache. A computed tomography scan revealed severe paranasal sinus disease and she was diagnosed with severe rhinosinusitis. She required extensive sinus surgery, and sinus cultures demonstrated heavy growth of MRSA and scant growth of *B gladioli*. She was initially treated with intravenous and topical vancomycin. Her immunosuppressive regimen was modified with a reduction in her maintenance prednisone dose and continuation of her second sinus surgery demonstrated light growth of both MRSA and *B gladioli*. She underwent additional sinus surgery that did not improve her symptoms. Sinus cultures at the time of her second sinus surgery demonstrated light growth of both MRSA and *B gladioli*. She was placed on intravenous vancomycin, meropenem, ceftazidime, oral trimethoprim-sulfamethoxazole and topical gentamicin. Although she initially improved following this treatment, she went on to develop bilateral purulent otitis media, mastoiditis and petrous bone apicitis (Figure 1). Subsequent sinus cultures demonstrated heavy growth of *B gladioli*. Her overall clinical condition progressively deteriorated, and she developed persistent *B gladioli* bacteremia, which developed resistance to all available antibiotics except piperacillin-tazobactam. Unfortunately, despite six months of continuous broad-spectrum intravenous antibiotics and six sinus surgeries, she eventually succumbed to the infection and died 18 months following lung transplantation.

**DISCUSSION**

We contribute to a growing body of evidence that *B gladioli* infection in CF patients prelung transplant can result in significant posttransplant morbidity and mortality (3-5). Our described case of a CF patient with chronic respiratory infection involving *B gladioli* prelung transplant tragically resulted in locally invasive sinus disease, persistent bacteremia and death 18 months post-transplant. Although MRSA may have contributed initially to her sinus disease, *B gladioli* became the primary pathogen because her clinical deterioration correlated closely with heavy growth of *B gladioli* from the sinuses and subsequent bacteremia. Her sinus infection was exceedingly difficult to control despite continuous intravenous antibiotics in the face of underlying immunosuppression, challenges achieving local source control and...
eventual development of antibiotic resistance. Interestingly, she did not grow B gladioli in her transplanted lungs and did not demonstrate evidence of allograft dysfunction based on symptoms, spirometry or chest imaging. The present case report follows a recently documented case of a CF lung transplant recipient with a mediastinal abscess due to B gladioli diagnosed postlung transplant that was also difficult to control but eventually responded to a prolonged course of intravenous antibiotics and surgical debridement (3).

Although there is general consensus of poor post-transplant outcomes in CF patients harbouring Burkholderia cepacia complex (Bcc) (2), experience with B gladioli infection is limited. Several distinct species constitute what is now referred to as Bcc, with apparent considerable variation with respect to their virulence in CF patients. Based on small studies, some centres have revised their lung transplant eligibility criteria to exclude B cepacia-infected patients, while offering transplant to patients harbouring other Bcc genomovars (5). Although B gladioli are phenotypically very similar to genomovars of Bcc, they are molecularly distinct and, therefore, have been classified as an independent species due to the availability of advanced molecular identification techniques (1). Studies have suggested more transient infection, less antibiotic resistance and absence of patient-to-patient transmission with B gladioli compared with Bcc (1).

Kennedy et al (4) conducted a review investigating postlung transplant outcomes in CF patients’ infected/colonized with B gladioli, summarizing three new cases and four previous cases from the literature. One of seven patients died as a direct result of B gladioli infection; however, that patient exhibited evidence of disseminated disease before lung transplant. The remaining six patients responded favourably to antibiotic therapy post-transplant. In light of these findings, the authors concluded that caution should be exercised, but that pre-transplant infection with B gladioli should not contraindicate lung transplantation in patients with CF. A more recent retrospective review by Murray et al (5), utilizing data from the United States CF Foundation Patient Registry, demonstrated greater post-transplant mortality in 14 CF lung transplant recipients infected with B gladioli compared with noninfected recipients, with an HR of 2.23 (P=0.04).

The present case adds to the growing body of evidence characterizing considerable morbidity and mortality related to opportunistic B gladioli infection in CF lung transplant recipients. This information suggests that the identification of B gladioli in pretransplant CF patients warrants reconsideration as a possible important relative contraindication to lung transplantation, similar to Bcc.

REFERENCES